InvestorWire NewsRoom


Genprex Inc. (NASDAQ: GNPX) Secures Exclusivity for REQORSA(R)-Keytruda(R) Drug Combination in China with Chinese Patent
July 28, 2023

Genprex Inc. (NASDAQ: GNPX) Secures Exclusivity for REQORSA(R)-Keytruda(R) Drug Combination in China with Chinese Patent

  • Genprex recently received a patent in China covering the use of its drug candidate REQORSA(R) immunogene therapy in combination with PD-1 antibodies, such as Keytruda(R), to treat cancers
  • The REQORSA-Keytruda drug combination is the subject of Genprex’s ongoing Acclaim-2 clinical trial, which targets patients with advanced, metastatic non-small cell lung cancer whose disease progressed after treatment with Keytruda
  • The company has received patent protection for the REQORSA-Keytruda drug combination in the U.S., Japan, Australia, Russia, Mexico, and China, meaning the company has secured exclusivity in many of the largest markets
  • The granted patents, three Fast Track Designations, and positive preclinical and clinical data are poised to help the company accelerate its clinical development of REQORSA in its various development programs

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company on a mission to develop life-changing therapies for patients with cancer and diabetes, recently received a patent in China – Genprex China Patent No: 201780076886.X – from the China National Intellectual Property Administration. The granted patent broadly covers the use of the company’s drug candidate REQORSAI immunogene therapy in combination with PD-1 antibodies, such as KeytrI(R), to treat cancers (

The REQORSA gene therapy in combination with Keytruda is the subject of the company’s ongoing Acclaim-2 clinical trial for the treatment of non-small cell lung cancer (“NSCLC”). In this trial, the company is enrolling and treating patients with advanced, metastatic NSCLC whose disease progressed after treatment with Keytruda. The first patient was dosed in this study in April of last year (

Against the backdrop of the ongoing study, Thomas Gallagher, Esq., Senior Vice President of Intellectual Property and Licensing at Genprex, described how the patent granted in China provides Genprex with important additional protection for the use of the REQORSA and PD-1 antibody combination.

“Now with the latest patent grant in China, we have secured exclusivity for the use of this drug combination for the treatment of cancer in some of the most important markets in the world.  The company already has received patent protection in the U.S., Australia, Mexico, Japan and Russia.  This patent protection prevents others from using this drug combination to treat cancer in these jurisdictions,” Gallagher explains.

REQORSA uses the company’s non-viral ONCOPREX(R) Nanoparticle Delivery System, a systemic gene therapy platform for cancer. The system encapsulates within lipid nanoparticles a plasmid that expresses the TUSC2 tumor suppressor gene, creating the REQORSA drug product. The company then intravenously administers the encapsulated plasmid, which is then taken up by the tumor cells, after which the tumor suppressor genes express proteins that are missing or found in low quantities in these cells (

According to the company, “REQORSA has a multimodal mechanism of action whereby it interrupts cell signaling pathways that cause replication and proliferation of cancer cells, re-establishes pathways for programmed cell death (apoptosis) in cancer cells, and modulates the immune response against cancer cells.” This lead product candidate is initially being developed in combination with prominent cancer drugs Tagrisso(R), Keytruda(R), and Tecentriq(R) to treat NSCLC and small cell lung cancer (“SCLC”) (

Having received three separate Fast Track Designations from the U.S. Food and Drug Administration (“FDA”) for its combination therapies with Tagrisso, Keytruda and Tecentriq, the company looks forward to accelerating the clinical development of REQORSA and potentially providing new treatments for patients. Moreover, Genprex’s growing patent portfolio is expected to boost these clinical development efforts.

For more information, visit the company’s website at

NOTE TO INVESTORS: The latest news and updates relating to GNPX are available in the company’s newsroom at

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published:

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
[email protected]

Get Started with InvestorWire

To distribute a release in the next 24 hours. Contact our client services team.

(862) 930-1404

Distribute a press release. Submit your release to get started.

Submit Press Release

Set up a Live demonstration. Schedule a date and time that works for you.

Schedule a LIVE Demo

Press Distribution

Explore Press Distribution Solutions

All releases include an unlimited word count* with full wire-grade syndication, our press release enhancement service, and a follow-up InvestorNewsBreak article distributed to thousands of editorial syndication partners.

Discover Add-on Solutions

Increase the impact of your achievements by adding these exclusive solutions from InvestorWire, delivered in conjunction with the InvestorBrandNetwork (IBN).